The rationale for this study is to further explore if development of antibodies against TNF-α blocking agents is associated with reduced clinical effect/worsened clinical outcome. An important aspect of the study is to carry out an exploratory analysis of the immunogenicity of the 4 recommended TNF-α blockers in the treatment of RA in Denmark, using the same cell-based assay.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01691014?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
